Patents for nucleic acid analogues
Novosibirsk developers of gene-directed drugs will patent them in the USA, Europe and China
Scientists of the Novosibirsk Institute of Chemical Biology and Fundamental Medicine (IHBFM) of the Siberian Branch of the Russian Academy of Sciences, who discovered in early 2016 a new class of chemical compounds – an analogue of RNA and DNA nucleic acids, which can serve as the basis for the creation of new generation drugs – along with Russia plan to patent these drugs in the USA, Europe, China and Korea. This was announced to TASS by Maxim Kupryushkin, general director of the resident business incubator of the Novosibirsk Akademgorodok Technopark (Akadempark), created to promote the development.
"We have found funding for this process and now we intend to patent the development in the USA, Europe, China and Korea. In parallel, work is underway with Rospatent to obtain a Russian patent," Kupryushkin said. According to him, the developer plans to patent in each country a whole class of substances on the basis of which drugs can be created. This will open up more opportunities for Novosibirsk developers. Kupryushkin did not specify when patents could be obtained.
Compounds discovered in the IHBFM SB RAS are analogues of DNA and RNA nucleic acids with specified properties. This approach has a number of advantages over traditional treatment methods, for example, antibiotic treatment. In particular, they are not recognized by enzymes designed to destroy foreign bodies, which are small molecules that enter the body during antibiotic treatment. Synthetic DNA fragments can be embedded in the structure of a malicious organism and "turn off" a certain gene, preventing the organism from reproducing.
Thus, the developers assure, it is potentially possible to defeat any viral and other infectious diseases. According to Kupryushkin, there are analogues of this technology abroad, but the range of its possible applications is very wide, and the mechanism of action is quite complex. Therefore, all developers are partners rather than competitors, whose research complements each other.
Portal "Eternal youth" http://vechnayamolodost.ru
17.03.2017